Peer-reviewed papers

1. Rasha Alhiary, Aaron S Kesselheim, Sarah ME Gabriele, Reed F Beall, S Sean Tu, and William B Feldman. “Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists.” JAMA, 2023. Available here.
2. Sarah ME Gabriele, William B Feldman. “The Problem of Limited-Supply Agreements for Medicare Price Negotiation.” JAMA, 2023. Available here.
3. Horrow, Caroline, Sarah ME Gabriele, S Sean Tu, Ameet Sarpatwari, and Aaron S Kesselheim. “Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.” JAMA Internal Medicine, 2024. Available here.
4. Martin, Matthew J, Sarah ME Gabriele, Aaron S Kesselheim, and S Sean Tu. “Characteristics of Academic Inventors on Government-Linked US Drug Patents.” JAMA, 2024. Available here.
5. Tu, S Sean, Dinis Cheian, Sarah ME Gabriele, Benjamin N Rome, and Aaron S Kesselheim. “The Cost of Drug Patent Expiration Date Errors.” Nature Biotechnology, 2024. Available here.
6. Rasha Alhiary, Sarah ME Gabriele, Aaron S Kesselheim, S Sean Tu, and William B Feldman. “Delivery Device Patents on GLP-1 Receptor Agonists.” JAMA, 2024. Available here.
7. Sarah ME Gabriele, Martin, Matthew J, Aaron S Kesselheim, and S Sean Tu. “The Strength and Importance of Government-Funded Patents for Approved Drugs” Nature Biotechnology, 2025. Available here.
   • Sarah ME Gabriele, Martin, Matthew J, Aaron S Kesselheim, and S Sean Tu. “Reply: The Strength and Importance of Government-Funded Patents for Approved Drugs” Nature Biotechnology, 2025 (forthcoming).
8. Theodore Teng, S. Sean Tu, Helen Mooney, Liam Bendicksen, Sarah ME Gabriele, Olivier J. Wouters, William B. Feldman. “Tertiary patents on drugs approved by the FDA, 1986-2023.” JAMA Health Forum, 2025 (forthcoming).

Other Writing

1. Sarah ME Gabriele, “Written submission to the U.S. International Trade Commission in connection with Inv. No. 332-596, COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities. May 5, 2023.” – Cited in final report by the U.S. International Trade Commission. Available here.
2. Sarah ME Gabriele, Bill of Health blog posts. Available here.

Work-in-progress

1. Sarah ME Gabriele, Aaron S Kesselheim, and Benjamin R. Rome. “Opportunities for State Medicaid savings by preferring brand-name drugs over generics”. Abstracts published in Value in Health. Available here and here.
2. Sarah ME Gabriele, Alexander Egilman, Joseph Daval, Aaron S Kesselheim. “Launching at Risks: A Comparative Analysis of Generic Marketing Entry in The United States and Europe”.
3. William B Feldman, Sarah ME Gabriele, and Aaron S Kesselheim. “Characterizing Paragraph IV Certifications, 2003-2025”.